Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives

Avidity Biosciences (RNA) reported a net loss of US$237.1 million for FY 2025, bringing its trailing 12-month net loss to US$684.6 million against total revenue of US$18.8 million. While analysts forecast 51.4% annual revenue growth, challenging the current loss-making trend, critics point to expanding losses and a P/B ratio higher than the industry average. Despite a significant DCF fair value indicating undervaluation, the company faces skepticism regarding its path to profitability and shareholder dilution.